Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial-March 2024-www.financetom.com

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025 4:22 AM

April 7 (Reuters) - Rhythm Pharmaceuticals ( RYTM ) said

on Monday that its experimental drug to treat a rare obesity

disorder met the main goal in a late-stage trial.

Previous page： Google Introduces Arm-Based Data Center Processor Next page： Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google Introduces Arm-Based Data Center Processor

Apr 9, 2024

08:51 AM EDT, 04/09/2024 (MT Newswires) -- Alphabet's (GOOG, GOOGL) Google ( GOOG ) on Tuesday introduced its first custom Arm-based processor designed for data centers. The chip, called Axion, provides up to 30% better performance compared with the fastest general-purpose Arm-based instances available in the cloud today, Google ( GOOG ) said in a blog post. Google ( GOOG...

Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access

Apr 9, 2024

08:49 AM EDT, 04/09/2024 (MT Newswires) -- Pfizer ( PFE ) said key data from an ongoing phase 3 clinical trial of its Abrysvo vaccine, which the pharmaceutical giant is developing for the treatment of respiratory syncytial virus, or RSV, met endpoints and it's going to seek wider access for the shot. The study evaluating a single dose of the...

Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study

Apr 9, 2024

08:49 AM EDT, 04/09/2024 (MT Newswires) -- Alkermes ( ALKS ) said Tuesday that its phase 1b study of ALKS 2680, a once-daily potential treatment for narcolepsy, showed enhanced wakefulness in patients with narcolepsy type 2 and idiopathic hypersomnia. ALKS 2680 showed clinically meaningful and statistically significant improvements in mean sleep latency compared with placebo across all doses tested in...

Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints

Apr 9, 2024

08:57 AM EDT, 04/09/2024 (MT Newswires) -- Pfizer ( PFE ) said Tuesday that its current pivotal phase 3 trial of Abrysvo against placebo in participants aged 18 to 59 years met primary endpoints. The patients were at an increased risk of developing respiratory syncytial virus-associated lower respiratory tract disease, the company said. In the trial, patients attained at least...